Susquehanna International Group, LLP Marker Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2022 May 16, 2022	BUY	$0.37 - $1.0 $9,065 - $24,500	24,500 Added 184.21%	37,800 $17,000
Q4 2021 Feb 14, 2022	SELL	$0.95 - $1.72 $65,265 - $118,164	-68,700 Reduced 83.78%	13,300 $13,000
Q3 2021 Nov 15, 2021	SELL	$1.68 - $2.88 $245,784 - $421,344	-146,300 Reduced 64.08%	82,000 $139,000
Q2 2021 Aug 11, 2021	BUY	$1.88 - $3.56 $175,216 - $331,792	93,200 Added 68.99%	228,300 $637,000
Q1 2021 May 17, 2021	BUY	$1.47 - $3.29 $165,228 - $369,796	112,400 Added 495.15%	135,100 $303,000
Q4 2020 Feb 16, 2021	SELL	$1.36 - $1.75 $11,016 - $14,175	-8,100 Reduced 26.3%	22,700 $33,000
Q3 2020 Nov 16, 2020	BUY	$1.5 - $2.2 $9,000 - $13,200	6,000 Added 24.19%	30,800 $46,000
Q2 2020 Aug 14, 2020	SELL	$1.69 - $2.79 $133,679 - $220,689	-79,100 Reduced 76.13%	24,800 $51,000
Q3 2019 Nov 14, 2019	BUY	$4.1 - $9.0 $353,419 - $775,800	86,200 Added 487.01%	103,900 $531,000
Q2 2019 Aug 14, 2019	BUY	$5.15 - $7.92 $35,535 - $54,648	6,900 Added 63.89%	17,700 $140,000
Q4 2018 Feb 14, 2019	BUY	$4.2 - $9.74 $45,360 - $105,192	10,800 New	10,800 $60,000

475K

Ticker MRKR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,599,200
Market Cap $164M
Description
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufact...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.